{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:35:13Z","timestamp":1793907313144,"version":"4.8.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Bispecific antibodies (BsAbs) are widely used for the treatment of multiple myeloma (MM), but their long-term safety still provokes concerns.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adverse event (AE) data on teclistamab, talquetamab, and elranatamab between 1 August 2022 and 30 September 2024 were retrieved from the Food and Drug Administration\u2019s AE Reporting System (FAERS) database by use of Open Vigil 2.1. AEs were categorized by preferred terms (PTs) and system organ classes (SOCs) as defined by MedDRA. As widely used statistical measures in pharmacovigilance, proportional reporting (PRR) and reporting odds ratios (ROR) were employed to identify potential safety signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total 2,789,182 reports on AEs were retrieved, including 811 for teclistamab, 446 for talquetamab and 302 for elranatamab. Significant associations with immune system disorders, nervous system disorders, benign, malignant and unspecified (incl cysts and polyps) neoplasms, and hepatobiliary disorders were found for all three BsAbs. Common PTs included cytokine release syndrome (CRS), neurotoxicity, immune effector cell-associated neurotoxicity syn-drome (ICANS), pyrexia, and neutropenia. Meanwhile, signal values varied among the three BsAbs. Notably, new safety signals numbered 14, 4, and 5 were identified for teclistamab, talquetamab, and elranatamab, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Adverse event signals were demonstrated to vary among the three BsAbs used in MM. Significant safety signals identified in the FAERS database which were consistent with previously reported clinical trial data. Furthermore, each BsAb exhibited several novel signals. These findings provide decision-makers and healthcare providers with valuable insights into clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1593405","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T05:33:16Z","timestamp":1755063196000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiaoling","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma.","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"m3176","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma.","volume":"370","author":"Shah","year":"2020","journal-title":"Bmj."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology.","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1002\/ajh.26628","article-title":"Bispecific T-cell engagers for treatment of multiple myeloma.","volume":"98","author":"Ravi","year":"2023","journal-title":"Am J Hematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/jco.23.00512","article-title":"Chimeric antigen receptor T-Cell and bispecific antibody therapy in multiple myeloma: moving into the future.","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e205-e16","DOI":"10.1016\/s1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/s0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: first approval.","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs."},{"key":"B9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma.","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40265-023-01954-w","article-title":"Elranatamab: first approval.","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3324\/haematol.2023.283931","article-title":"Talquetamab in multiple myeloma.","volume":"109","author":"Liu","year":"2024","journal-title":"Haematologica."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s40265-023-01945-x","article-title":"Talquetamab: first approval.","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma.","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e00255-69","DOI":"10.1016\/s1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European myeloma network.","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/antib12020038","article-title":"The role of bispecific antibodies in relapsed refractory multiple myeloma: a systematic review.","volume":"12","author":"Khanam","year":"2023","journal-title":"Antibodies."},{"key":"B17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12935-023-03045-y","article-title":"Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis.","volume":"23","author":"Noori","year":"2023","journal-title":"Cancer Cell Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40360-024-00741-x","article-title":"Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system.","volume":"25","author":"Zhao","year":"2024","journal-title":"BMC Pharmacol Toxicol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1251961","DOI":"10.3389\/fphar.2024.1251961","article-title":"A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.","volume":"15","author":"Pan","year":"2024","journal-title":"Front Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/14740338.2024.2338250","article-title":"Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA adverse event reporting system.","volume":"23","author":"Zhao","year":"2024","journal-title":"Expert Opin Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","article-title":"OpenVigil\u2013free eyeballs on AERS pharmacovigilance data.","volume":"30","author":"B\u00f6hm","year":"2012","journal-title":"Nat Biotechnol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source.","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1190379","DOI":"10.3389\/fimmu.2023.1190379","article-title":"Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures.","volume":"14","author":"Shah","year":"2023","journal-title":"Front Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome.","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/cpt.3223","article-title":"Impact of treatment modality and route of administration on cytokine release syndrome in relapsed or refractory multiple myeloma: a meta-analysis.","volume":"115","author":"Soltantabar","year":"2024","journal-title":"Clin Pharmacol Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/cncr.34756","article-title":"Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma.","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1177\/10781552221140320","article-title":"Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting.","volume":"29","author":"Lipe","year":"2023","journal-title":"J Oncol Pharm Pract."},{"key":"B28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1182\/hematology.2023000435","article-title":"Managing side effects: guidance for use of immunotherapies in multiple myeloma.","volume":"2023","author":"Liang","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"B29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11899-024-00740-z","article-title":"Management of toxicities associated with BCMA, GPRC5D, and FcRH5-targeting bispecific antibodies in multiple myeloma.","volume":"19","author":"Pan","year":"2024","journal-title":"Curr Hematol Malig Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"103453","DOI":"10.1016\/j.critrevonc.2021.103453","article-title":"Rethinking mechanisms of neurotoxicity with BCMA directed therapy.","volume":"166","author":"Mohyuddin","year":"2021","journal-title":"Crit Rev Oncol Hematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management.","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1348955","DOI":"10.3389\/fimmu.2024.1348955","article-title":"Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3389\/fimmu.2020.00762","article-title":"Bispecific, T-Cell-recruiting antibodies in B-cell malignancies.","volume":"11","author":"Lejeune","year":"2020","journal-title":"Front Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3324\/haematol.2023.283590","article-title":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.","volume":"109","author":"Hammons","year":"2024","journal-title":"Haematologica."},{"key":"B36","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect."},{"key":"B37","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study.","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer."},{"key":"B38","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e7048","DOI":"10.1002\/cam4.7048","article-title":"Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: real-world evidence from Sweden.","volume":"13","author":"Uttervall","year":"2024","journal-title":"Cancer Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2643-3230.Bcd-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies.","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"B41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"E349","DOI":"10.1002\/ajh.27071","article-title":"Increased risk of infection reporting with anti-BCMA bispecific monoclonal antibodies in multiple myeloma: a worldwide pharmacovigilance study.","volume":"98","author":"Contejean","year":"2023","journal-title":"Am J Hematol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/ddg.15502","article-title":"Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review.","volume":"22","author":"Mansilla-Polo","year":"2024","journal-title":"J Dtsch Dermatol Ges."},{"key":"B44","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG family member, GPRC5D, is associated with hard-keratinized structures.","volume":"122","author":"Inoue","year":"2004","journal-title":"J Invest Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1182\/blood-2021-146868","article-title":"Updated phase 1 results from monumenTAL-1: first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma.","volume":"138","author":"Krishnan","year":"2021","journal-title":"Blood."},{"key":"B46","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jaad.2023.08.094","article-title":"Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab.","volume":"90","author":"Lery","year":"2024","journal-title":"J Am Acad Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jdcr.2022.11.013","article-title":"Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma.","volume":"31","author":"Narayan","year":"2023","journal-title":"JAAD Case Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany.","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e011200","DOI":"10.1136\/jitc-2024-011200","article-title":"Characteristics of second primary malignancies following bispecific antibodies therapy.","volume":"13","author":"Liang","year":"2025","journal-title":"J Immunother Cancer."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s41591-025-03499-9","article-title":"Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody.","volume":"31","author":"Braun","year":"2025","journal-title":"Nat Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e012384","DOI":"10.1136\/jitc-2025-012384","article-title":"Correspondence on \u2018characteristics of second primary malignancies following bispecific antibodies therapy\u2019 by Liang et al.","volume":"13","author":"Jin","year":"2025","journal-title":"J Immunother Cancer."},{"key":"B52","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41577-021-00537-8","article-title":"CD8(+) T cell metabolism in infection and cancer.","volume":"21","author":"Reina-Campos","year":"2021","journal-title":"Nat Rev Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41577-023-00843-3","article-title":"Clonal haematopoiesis and dysregulation of the immune system.","volume":"23","author":"Belizaire","year":"2023","journal-title":"Nat Rev Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"008518","DOI":"10.1136\/jitc-2023-008518","article-title":"Cardiovascular toxicities associated with bispecific T-cell engager therapy.","volume":"12","author":"Sayed","year":"2024","journal-title":"J Immunother Cancer."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1593405\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T05:33:17Z","timestamp":1755063197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1593405\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":54,"alternative-id":["10.3389\/fmed.2025.1593405"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1593405","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"article-number":"1593405"}}